Novo Nordisk filed a U.S. patent infringement lawsuit against Hims & Hers Health on February 9, 2026, alleging that the telehealth company’s compounded semaglutide weight‑loss pill violates U.S. Patent 8,129,343. The suit seeks a permanent injunction that would bar Hims & Hers from selling any compounded GLP‑1 products and damages for the alleged infringement.
The lawsuit follows Hims & Hers’ brief launch of a $49‑per‑month compounded semaglutide pill, which the company withdrew on February 7 after receiving an FDA warning and Novo’s threat of legal action. The pill had been a key growth engine, contributing an estimated 70% of the company’s online sales and driving a projected $1.7 billion run‑rate revenue. The injunction would force Hims & Hers to abandon its compounded GLP‑1 strategy, potentially eroding a significant portion of its revenue and tightening margins.
Market reaction was swift: Hims & Hers’ shares fell 16% on the day of the lawsuit announcement, reflecting investor concern that the loss of the weight‑loss segment would materially weaken the company’s growth trajectory. Novo Nordisk’s shares rose 5%, as the action was viewed as a protective measure for its own Wegovy® and Ozempic® product lines. Analysts noted that the lawsuit underscores the regulatory risk of mass‑marketing compounded drugs and signals a broader industry shift toward stricter enforcement of intellectual property rights.
From a business perspective, the lawsuit threatens to expose Hims & Hers to a new class of litigation and regulatory scrutiny that could limit its ability to offer low‑cost alternatives to branded GLP‑1 therapies. The company’s revenue mix, which had been heavily weighted toward the weight‑loss segment, will need to diversify, and the loss of that segment could accelerate margin compression. Novo Nordisk, meanwhile, is reinforcing its market dominance by protecting its patents and deterring competitors from offering unapproved knock‑offs.
The legal action also highlights the growing tension between pharmaceutical manufacturers and compounding pharmacies. While compounding is allowed for individualized patient needs, the FDA and drug makers are increasingly scrutinizing mass‑marketed alternatives. The lawsuit signals that Novo Nordisk is willing to use litigation to defend its intellectual property and maintain pricing power in the rapidly expanding GLP‑1 obesity market.
In summary, the lawsuit represents a significant regulatory and competitive challenge for Hims & Hers, potentially reshaping its product strategy and financial outlook, while reinforcing Novo Nordisk’s position as a guardian of its patented therapies.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.